ArticleScientific reports2025
PDIA3 rs2788, a risk factor for metabolic syndrome, interacted negatively with antihypertensive medications.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The clinical complex called metabolic syndrome (MetS) is caused by the interaction of genetic and cardiovascular risk factors. Protein disulfide isomerase family A member 3 (PDIA3) is a key endoplasmic reticulum protein which may contribute to MetS. This study aimed to evaluate how PDIA3 polymorphism is linked to MetS and its hypertension. Clinical indicators were measured in 2,379 individuals. The association of PDIA3 rs2788 with MetS was analyzed. Crossover analysis elucidated the crosstalk between PDIA3 rs2788 and antihypertensive treatment, and the synergistic effect on MetS. In this cross-sectional study, linear regression analysis showed that a positive linear correlation of rs2788 with systolic blood pressure (SBP, β = 5.818, p < 0.01) and diastolic blood pressure (DBP, β = 4.324, p < 0.01). Ordered logistic regression revealed that the rs2788 GG genotype was progressive with an increasing number of MetS components (component number: 2-5, both p < 0.05). In the longitudinal analysis, a multivariate logistic regression model adjusted for variable MetS components revealed that PDIA3 rs2788 confers a high risk of MetS incidence (OR: 1.585, 95% CI: 1.011-2.486; p < 0.05). Stratification analysis revealed that PDIA3 rs2788 correlated positively with SBP and DBP among female patients. The synergistic effect of antihypertensive treatment and PDIA3 rs2788 is negative among female patients (S < 1). PDIA3 rs2788 is a strong predictor for MetS in the studied Chinese population. In female patients, PDIA3 rs2788 interacted negatively in the association of MetS with antihypertensive treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.